Slide 1: Bactiguard Q2 2020
Bactiguard Q2 2020 Investor presentation - August 13th 2020 Cecilia Edström, CEO Gabriella Björknert Caracciolo, CFO
Slide 2: Global developments in Q2
Global developments in Q2 Major COVID-19 impact • Extensive lock-downs in many regions • Major declines in economic activity • Healthcare focus on COVID-19 patients US GDP* EU GDP* Q1: -1,3 Q2: -9,5 Q1: -1,3 Q2: -9,5 • Lower hospital admissions and utilization, postponed elective and non-urgent proc
Slide 3: Financial highlights
Financial highlights Strong growth and earnings development • Sales growth of 46% (45% currency adjusted) to MSEK 48.2 (33.0) • BIP sales of MSEK 25.4 (3.2) – in line with record Q4 quarter 2019 • Growth driven by BIP portfolio and integration of Vigilenz • EBITDA of MSEK 10.5 (5.7) • Improved EBITD
Slide 4: Operational highlights
Operational highlights Increasing need for infection prevention • Tests performed by the Swedish national Veterinary Institutes showed that 99.9% of the COVID-19 virus particles were killed after exposure to Hydrocyn aqua • New distribution agreement with Swedish online pharmacy Apotea • Establishin
Slide 5: Strengthening the management team
Strengthening the management team Gabriella Björknert Caracciolo new CFO • Education: MBA Stockholm university • Other assignments: Board member Bankgirocentralen, BGC • Background: Senior positions within SEB and Nordea and experience from Management Consulting • Other: o 20+ years experience from
Slide 6: COVID-19 impact
COVID-19 impact
Slide 7: Short-term COVID-19 impact
Short-term COVID-19 impact • Increased need for disinfectants, • Significant decrease in hospital behavioural changes – admissions for non-COVID patients calibrating ‘the new normal’ • Elective procedures and non- • Shortage of protective critical treatment on hold equipment and diagnostics • Lower
Slide 8: Longer term COVID-19 impact
Longer term COVID-19 impact Prevention is better than cure Increased need for infection control Trends: • Increasing awareness of infections • Behavioural changes will remain after pandemic subsides • Patients cautious in seeking healthcare • Increased demand for disinfectants and • Accelerating hea
Slide 9: Scalable business model
Scalable business model Expanding our portfolio for infection protection License agreements for various Proprietary product portfolio – applications with Bactiguard sold through distributors technology 9
Slide 10: Financial update
& Bactiguard Financial update
Slide 11: Strong performance driven by BIP portfolio
Strong performance driven by BIP portfolio Q2 2020 vs 2019 • Revenue Growth of 46%, (adjusted for currency 45%) • Strong sales growth in BIP- sales. Negative Covid-19 effect on license revenues. • EBITDA-margin increased to 22% (17%) • Bactiguard entered a new development phase with the strategic ac
Slide 12: Financial overview
Financial overview 2020 2019 Full MSEK Q1 Q2 YTD 6m RTM Q1 Q2 Q3 Q4 year Revenues 48,1 48,2 96,3 223,3 33,9 33,0 67,2 59,8 193,9 EBITDA 14,4 10,5 24,9 73,6 7,2 5,7 36,5 12,2 61,6 EBITDA margin % 30% 22% 26% 33% 21% 17% 54% 20% 32% Depreciations -10,5 -11,3 -21,8 -42,1 -10,6 -10,5 -10,6 -10,5 -42,1 w
Slide 13: Revenue distribution
Revenue distribution Income distribution 13
Slide 14: Cash flow and liquidity
Cash flow and liquidity • Positive operating cash flow for Q2 of MSEK 3.6 (-0.2) • Net Cash position of MSEK 16.3 (1.6) • Liquidity MSEK 46.3 • The Vigilenz acquisition was partly financed by debt and issue of new shares in Q2 14
Slide 15: Profitable growth
Profitable growth 60 000 100% 250 000 100% 223 299 51 345 90% 90% 50 000 48 211 193 929 80% 200 000 80% 70% 163 200 70% 40 000 33 037 60% 150 000 60% 30 000 50% 50% 40% 100 000 32% 33% 40% 20 000 22% 30% 30% 18% 17% 20% 50 000 14% 20% 10 000 10% 10% 0 0% 0 0% Q2 2018 Q2 2019 Q2 2020 2018 FY 2019 FY
Slide 16: Concluding remarks
Concluding remarks • Strong growth and earnings development • Broader BIP portfolio and increased market coverage through strategic acquisition of Vigilenz • COVID-19 has affected us all Global economic and healthcare challenges New opportunities that will remain beyond the pandemic • Bactiguard
Slide 17: Questions & Answers
Questions & Answers Cecilia Edström CEO Phone +46 8 440 58 80 cecilia.edstrom@bactiguard.se Gabriella Björknert Caracciolo CFO Phone +46 8 440 58 80 Gabriella.caracciolo@bactiguard.se 17
Slide 18: Upcoming financial reports
Upcoming financial reports November 05, 2020 Interim report for Q3 February 04, 2021 Year-end report for 2020 18